Optic Nerve Disorders Drug Development Pipeline Review, 2018
- Pages: 149
- Published: October 2018
- Report Code: GBIHC049IDB
This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication.
Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. There are 13 products in development for this indication.
LHON is an inherited form of vision loss. This condition usually begins in a person’s teens or twenties. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 16 products in development for this indication.
Optic neuritis refers to inflammation of the optic nerve. Symptoms include pain, vision loss, dyschromatopsia (impaired ability to perceive colors) and flashing lights. There are 12 products in development for this indication.
Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen.
Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
Neuritis
AC Immune SA
Aerie Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc
Allergan Plc
Altacor Ltd
Amarantus Bioscience Holdings Inc
Annexon Inc
Astellas Pharma Inc
Bactevo Ltd
Bial – Portela & Ca SA
BioAxone BioSciences Inc
Bionure Farma SL
Biovista Inc
Can-Fite BioPharma Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Chong Kun Dang Pharmaceutical Corp
coma
Commence Bio Inc
D. Western Therapeutics Institute Inc
Disarm Therapeutics Inc
Dompe Farmaceutici SpA
Elsalys Biotech SA
EyePoint Pharmaceuticals Inc
Eyevensys SAS
Fortify Therapeutics Inc
Fortress Biotech Inc
Gene Signal International SA
GenSight Biologics SA
Glaukos Corp
Graybug Vision Inc
Han Wha Pharma Co Ltd
Handok Inc
HitGen LTD
ID Pharma Co Ltd
InMed Pharmaceuticals Inc
Inspyr Therapeutics Inc
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Ixchel Pharma LLC
Khondrion BV
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratorios SALVAT SA
Laboratorios Sophia SA de CV
Lee’s Pharmaceutical Holdings Ltd
Lipocure Ltd
Meta-IQ ApS
MimeTech Srl
Mitobridge Inc
Mitochon Pharmaceuticals Inc
Mitotech SA
Nemus Bioscience Inc
Neurim Pharmaceuticals Ltd
NicOx SA
NoNO Inc
Novaliq GmbH
Novartis AG
Ocular Therapeutix Inc
Oculis ehf
Ohr Pharmaceutical Inc
Oncolys BioPharma Inc
Pivot Pharmaceuticals Inc
Profarma
Q BioMed Inc
Regenera Pharma Ltd
ReNetX Bio
Santen Pharmaceutical Co Ltd
Santhera Pharmaceuticals Holding AG
Senju Pharmaceutical Co Ltd
Shire Plc
Spark Therapeutics Inc
Stealth BioTherapeutics Inc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd
Teijin Pharma Ltd
TikoMed AB
Unity Biotechnology Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.